Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Amundi

Amundi reduced its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 7.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,729 shares of the biopharmaceutical company’s stock after selling 206 shares during the quarter. Amundi’s holdings in Intra-Cellular Therapies were worth $225,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the business. Lisanti Capital Growth LLC increased its stake in Intra-Cellular Therapies by 24.9% in the fourth quarter. Lisanti Capital Growth LLC now owns 72,600 shares of the biopharmaceutical company’s stock valued at $6,064,000 after purchasing an additional 14,485 shares during the last quarter. Candriam S.C.A. increased its stake in Intra-Cellular Therapies by 30.6% in the fourth quarter. Candriam S.C.A. now owns 214,320 shares of the biopharmaceutical company’s stock valued at $17,900,000 after purchasing an additional 50,188 shares during the last quarter. Inceptionr LLC acquired a new position in Intra-Cellular Therapies in the fourth quarter valued at $1,034,000. Raymond James Financial Inc. acquired a new position in Intra-Cellular Therapies in the fourth quarter valued at $76,451,000. Finally, Arizona State Retirement System increased its stake in Intra-Cellular Therapies by 0.8% in the fourth quarter. Arizona State Retirement System now owns 27,565 shares of the biopharmaceutical company’s stock valued at $2,302,000 after purchasing an additional 206 shares during the last quarter. 92.33% of the stock is currently owned by institutional investors and hedge funds.

Intra-Cellular Therapies Stock Up 0.0 %

Shares of NASDAQ ITCI opened at $131.65 on Friday. Intra-Cellular Therapies, Inc. has a fifty-two week low of $64.09 and a fifty-two week high of $131.67. The business has a 50 day moving average price of $128.61 and a two-hundred day moving average price of $97.41. The firm has a market cap of $14.00 billion, a PE ratio of -151.32 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. On average, analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on ITCI shares. Leerink Partnrs downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Mizuho downgraded Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and cut their price objective for the stock from $140.00 to $132.00 in a report on Monday, February 24th. StockNews.com began coverage on Intra-Cellular Therapies in a report on Thursday. They issued a “hold” rating on the stock. Royal Bank of Canada restated a “sector perform” rating and issued a $132.00 price objective (up from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Finally, Cantor Fitzgerald upgraded Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 14th. Ten investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $106.08.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.